← SynDRA
EC-5026
SynDRA canonical compound SYN2332897 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | EPHX2 |
|---|
| Mechanism of action | epoxide hydolase inhibitor |
|---|
| Indication | pain relief |
|---|
| Disease area | neurology/psychiatry |
|---|
All known targets
Mechanisms of action (all sources)
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- EC5026
- D5X8A5HWL0
- RefChem:136195
- BPN-19186
- MFCD32667032
- C18H23F4N3O3
- EC-5062
- UNII-D5X8A5HWL0
- orb1309721
- SCHEMBL17114596
- SCHEMBL29446585
- GTPL12750
- LHRXHTKENPCGSZ-NSHDSACASA-N
- BDBM409005
- BDBM727006
- GLXC-22394
- BPN19186
- EX-A3264
- US12251379, Compound 26
- AKOS037648812
- AT14069
- EC5026?
- US10377744, Compound No. 26
- AC-36370
- BS-15699
- DA-72992
- SY287906
- HY-135653
- CS-0113694
- T11147
- F547156
- 1-[3-fluoro-4-(trifluoromethoxy)phenyl]-3-[1-[(2S)-2-methylbutanoyl]piperidin-4-yl]urea
- SCHEMBL17130382
- US12251379, Compound 51
- HY-135653A
- JXC88532
- SCHEMBL17114593
- T9832
- BDBM409030
Look up EC-5026 in the interactive SynDRA portal →